| 2022-09-07 | +80.4% | expansion | Seeking Alpha | Imara jumps 69% on asset purchase agreement with Cardurion |
| 2026-01-08 | +67.4% | news | Seeking Alpha | Enliven surges after early-stage trial data for leukemia therapy |
| 2026-01-08 | +67.4% | news | Yahoo Finance | Assessing Enliven Therapeutics (ELVN) Valuation After Encouraging Phase 1b ENABLE Trial Data - Yahoo Finance |
| 2026-01-08 | +67.4% | news | PR Newswire | Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones - PR Newswire |
| 2026-01-08 | +67.4% | news | Benzinga | Why Is Enliven Therapeutics Stock Soaring Today? - Enliven Therapeutics (NASDAQ:ELVN) - Benzinga |
| 2026-01-08 | +67.4% | news | Investing.com | Enliven stock surges after positive CML drug trial data - Investing.com |
| 2026-01-08 | +67.4% | news | Seeking Alpha | Enliven surges on trial data for leukemia drug (ELVN:NASDAQ) - Seeking Alpha |
| 2026-01-07 | +53.9% | news | PR Newswire | Enliven Therapeutics Bolsters Board to Prepare for Next Phase of Development - PR Newswire |
| 2026-01-07 | +53.9% | executive | TipRanks | Enliven Therapeutics appoints new board chair amid transition - TipRanks |
| 2022-10-13 | +53.1% | M&A | Seeking Alpha | Cancer drug developer Enliven Therapeutics and Imara to merge in all-stock deal |
| 2024-03-19 | +50.5% | news | Seeking Alpha | Enliven Therapeutics announces $90M private placement to fund R&D activities |
| 2022-10-14 | +34.7% | news | Fierce Biotech | Enliven Therapeutics, troubled Imara set to merge with Roche-backed $165M fundraise - Fierce Biotech |
| 2022-04-05 | -29.0% | executive | Seeking Alpha | Imara slumps 39% as it plans to cull sickle cell/beta-thalassemia programs of tovinontrine after 2 trials disappoint |
| 2026-03-25 | +27.4% | earnings | MT Newswires | Mizuho Raises Price Target on Enliven Therapeutics to $45 From $41, Keeps Outperform Rating |
| 2026-03-25 | +27.4% | M&A | Investing.com | Enliven Therapeutics stock surges 28% on Merck-Terns deal - Investing.com |
| 2026-03-25 | +27.4% | news | Investing.com | Clear Street reiterates Enliven Therapeutics stock Buy on CML opportunity - Investing.com |
| 2026-03-25 | +27.4% | earnings | Yahoo Finance | Enliven Therapeutics (ELVN) Soars to 5-Year High as Analysts ‘Upbeat’ - Yahoo Finance |
| 2026-03-25 | +27.4% | news | Stock Titan | Enliven Therapeutics (ELVN) affiliate files to sell 45,000 shares via Jefferies - Stock Titan |
| 2026-03-25 | +27.4% | M&A | Stocktwits | Terns Buyout Deal Ignites Optimism For Enliven Therapeutics’s Blood Cancer Portfolio - Stocktwits |
| 2026-03-25 | +27.4% | M&A | Investing.com South Africa | Enliven Therapeutics stock surges 28% on Merck-Terns deal By Investing.com - Investing.com South Africa |
| 2026-03-25 | +27.4% | analyst | Kalkine Media | Enliven Therapeutics (NASDAQ:ELVN) Gains Attention After Price Target Adjustment - Kalkine Media |
| 2025-11-03 | -17.8% | news | PR Newswire | Enliven Therapeutics Announces Clinical Data in CML Patients with Atypical Fusion Transcripts at ASH 2025 Annual Meeting - PR Newswire |
| 2025-06-13 | +17.6% | legal | Seeking Alpha | Enliven Therapeutics stock falls after pricing capital raise of $200M via securities offering |
| 2025-06-13 | +17.6% | news | PR Newswire | Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - PR Newswire |
| 2025-06-13 | +17.6% | news | PR Newswire | Enliven Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants - PR Newswire |
| 2025-05-15 | -16.4% | earnings | Seeking Alpha | Enliven Therapeutics GAAP EPS of -$0.57 beats by $0.01 |
| 2025-06-03 | +15.9% | news | TradingView | ELVN Stock Price and Chart — NASDAQ:ELVN - TradingView |
| 2025-12-11 | -15.6% | news | PR Newswire | Enliven Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing Rules - PR Newswire |
| 2025-12-11 | -15.6% | executive | TipRanks | Enliven Therapeutics Appoints Richard Fair as CEO - TipRanks |
| 2024-03-11 | -15.2% | news | CNN | symbol__ Stock Quote Price and Forecast - CNN |
| 2026-03-24 | +15.1% | news | Stock Titan | Enliven Therapeutics (Nasdaq: ELVN) founder files Form 144 to sell 100,000 - Stock Titan |
| 2026-03-26 | +12.7% | earnings | Insider Monkey | Enliven Therapeutics (ELVN) Soars to 5-Year High as Analysts ‘Upbeat’ |
| 2026-03-26 | +12.7% | analyst | Investing.com | Enliven Therapeutics stock price target raised to $56 by H.C. Wainwright - Investing.com |
| 2023-02-26 | -11.9% | news | Zacks Investment Research | Should I buy Enliven Therapeutics, Inc. (ELVN) - Zacks Investment Research |
| 2023-02-26 | -11.9% | analyst | Zacks Investment Research | What is the current Price Target and Forecast for Enliven Therapeutics, Inc. (ELVN) - Zacks Investment Research |
| 2023-02-26 | -11.9% | earnings | MarketBeat | Enliven Therapeutics (ELVN) Stock Price, News & Analysis - MarketBeat |
| 2023-02-26 | -11.9% | earnings | MarketBeat | Top Enliven Therapeutics (ELVN) Competitors 2026 - MarketBeat |
| 2025-05-14 | -11.7% | news | PR Newswire | Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML and Oral Presentation at the EHA 2025 Congress - PR Newswire |
| 2026-04-06 | +10.6% | analyst | Insider Monkey | Enliven (ELVN) Gets Higher Price Targets From H.C. Wainwright and Mizuho |
| 2026-04-06 | +10.6% | analyst | Yahoo Finance | Enliven (ELVN) Gets Higher Price Targets From H.C. Wainwright and Mizuho - Yahoo Finance |
| 2026-04-06 | +10.6% | news | Cổng thông tin điện tử Tỉnh Sơn La | Is Enliven Therapeutics (ELVN) Stock a Buy or Sell | Price at $38.94, Up 0.28% - Trending Volume Leaders - Cổng thông tin điện tử Tỉnh Sơn La |
| 2023-11-09 | -10.1% | earnings | Seeking Alpha | Enliven Therapeutics GAAP EPS of -$0.51 |
| 2023-02-23 | +9.5% | news | Stock Titan | Latest ELVN News - Enliven Therapeutics Reports Fourth Quarter... - Stock Titan |
| 2026-03-19 | +8.5% | news | Stock Titan | Enliven Therapeutics (ELVN) CMO sells 5,000 shares after option exercise - Stock Titan |
| 2024-08-14 | +8.4% | earnings | Seeking Alpha | Enliven Therapeutics GAAP EPS of -$0.41 |
| 2024-11-13 | -7.7% | earnings | Seeking Alpha | Enliven Therapeutics GAAP EPS of -$0.48 beats by $0.02 |
| 2026-04-07 | +7.7% | earnings | MarketBeat | Enliven Therapeutics (NASDAQ:ELVN) Sets New 12-Month High - Should You Buy? - MarketBeat |
| 2026-04-07 | +7.7% | news | timothysykes.com | Enliven Therapeutics Regains Attention as Stock Prices Soar - timothysykes.com |
| 2026-04-07 | +7.7% | news | TipRanks | Why Enliven Therapeutics Stock Is Surging Today - TipRanks |
| 2026-04-07 | +7.7% | M&A | StocksToTrade | Merck’s Acquisition Sparks Surge in Enliven Therapeutics - StocksToTrade |
| 2026-04-07 | +7.7% | M&A | timothysykes.com | Merck’s Acquisition Ups Competition in Pharmaceuticals, Enliven Shines - timothysykes.com |
| 2025-09-12 | -7.6% | news | Seeking Alpha | Enliven Therapeutics, Inc. (ELVN) Presents at 13th Annual Meeting of the Society of Hematologic Oncology - Slideshow |
| 2026-01-09 | +6.8% | news | Investing.com | Enliven Therapeutics stock hits 52-week high at $25.64 - Investing.com |
| 2022-03-15 | +6.6% | earnings | Seeking Alpha | Imara (IMRA) CEO, Rahul Ballal on Q4 2021 Results - Earnings Call Transcript |
| 2023-08-11 | -6.6% | earnings | Seeking Alpha | Enliven Therapeutics GAAP EPS of -$0.41 beats by $0.04 |
| 2026-01-31 | +6.0% | executive | Yahoo Finance | Enliven Therapeutics Chief Scientific Officer Sells ELVN 20K Shares Worth Over $500k - Yahoo Finance |
| 2026-01-22 | -5.8% | news | Investing.com | Lyssikatos, Enliven Therapeutics CSO, sells $535k in ELVN stock - Investing.com |
| 2026-01-22 | -5.8% | news | Investing.com | Enliven Therapeutics director Heyman sells $32,901 in stock - Investing.com |
| 2025-06-17 | -5.7% | news | Yahoo Finance | Enliven Therapeutics, Inc. (ELVN) Backed by Goldman Sachs After Strong Trial Data - Yahoo Finance |
| 2024-02-12 | -5.5% | news | Seeking Alpha | Enliven Therapeutics Maybe Improving Kinase Inhibitors, But Too Early To Tell The Impact |
| 2026-03-29 | -5.4% | news | Yahoo Finance | Assessing Enliven Therapeutics (ELVN) Valuation After Strong Recent Share Price Momentum - Yahoo Finance |
| 2026-03-28 | -5.4% | executive | Motley Fool | Enliven Theraeutics' (ELVN) Chief Medical Officer Sold 40,000 Shares for $1.2 Million |
| 2026-03-28 | -5.4% | executive | The Motley Fool | Enliven Theraeutics' (ELVN) Chief Medical Officer Sold 40,000 Shares for $1.2 Million - The Motley Fool |
| 2026-03-28 | -5.4% | executive | Yahoo Finance | Enliven Theraeutics' (ELVN) Chief Medical Officer Sold 40,000 Shares for $1.2 Million - Yahoo Finance |
| 2026-03-28 | -5.4% | executive | AOL.com | Enliven Theraeutics' (ELVN) Chief Medical Officer Sold 40,000 Shares for $1.2 Million - AOL.com |
| 2025-04-22 | +5.4% | news | Seeking Alpha | Enliven Therapeutics: Awaiting Additional Trial Data |
| 2025-04-22 | +5.4% | news | Seeking Alpha | Enliven Therapeutics: Awaiting Additional Trial Data (NASDAQ:ELVN) - Seeking Alpha |
| 2026-04-22 | -5.0% | news | Stock Titan | Enliven Therapeutics (ELVN) CMO sells 5,000 shares after option exercise - Stock Titan |
| 2026-03-27 | -4.8% | legal | MT Newswires | Enliven Therapeutics Insider Sold Shares Worth $1,404,024, According to a Recent SEC Filing |
| 2026-03-27 | -4.8% | news | Stock Titan | Enliven (NASDAQ: ELVN) CMO exercises options and sells 40K shares - Stock Titan |
| 2026-01-13 | +4.8% | news | Seeking Alpha | Enliven Therapeutics: Springing Into 2026 With Data, But I'm Still Cautious |
| 2026-01-13 | +4.8% | news | Seeking Alpha | Enliven Therapeutics: Springing Into 2026 With Data, But I'm Still Cautious (NASDAQ:ELVN) - Seeking Alpha |
| 2026-01-13 | +4.8% | news | Investing.com India | Enliven Therapeutics CSO Lyssikatos sells $3.47 million in shares By Investing.com - Investing.com India |
| 2024-05-11 | +4.5% | earnings | MarketBeat | Enliven Therapeutics (ELVN) Stock Forecast and Price Target 2026 - MarketBeat |
| 2023-03-22 | +4.3% | news | TradingView | Technical Analysis of Enliven Therapeutics, Inc. (NASDAQ:ELVN) - TradingView |
| 2025-08-13 | +4.3% | legal | Seeking Alpha | Enliven files automatic mixed securities shelf |
| 2025-08-13 | +4.3% | earnings | Seeking Alpha | Enliven Therapeutics GAAP EPS of -$0.49 beats by $0.04 |
| 2026-02-25 | +4.3% | news | PR Newswire | Enliven Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference |
| 2026-02-25 | +4.3% | news | PR Newswire | Enliven Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference - PR Newswire |
| 2025-04-06 | -4.2% | news | Intellectia AI | ELVN Forecast — Price Prediction for 2026. Should I Buy ELVN? - Intellectia AI |
| 2022-09-29 | +4.0% | news | Seeking Alpha | Imara: Potential Liquidation |
| 2026-04-20 | -3.8% | analyst | Cổng thông tin điện tử Tỉnh Sơn La | Enliven Therapeutics (ELVN) Stock: Risk Analysis (Slight Loss) 2026-04-20 - Top Analyst Buy Signals - Cổng thông tin điện tử Tỉnh Sơn La |
| 2026-04-18 | -3.3% | news | UBND thành phố Hải Phòng | Enliven Therapeutics (ELVN) Stock Investment Grade (Smart Money Active) 2026-04-18 - Crowd Trend Signals - UBND thành phố Hải Phòng |
| 2026-04-18 | -3.3% | news | HarianBasis.co | Enliven Therapeutics Stock Surges 194 Percent Amid CML Market Interest - HarianBasis.co |
| 2026-04-13 | -3.2% | earnings | MarketBeat | Enliven Therapeutics (NASDAQ:ELVN) Stock Price Down 4.2% - What's Next? - MarketBeat |
| 2023-08-18 | +2.9% | news | Seeking Alpha | Enliven Therapeutics: Preclinical Company With Interesting Value Proposition |
| 2023-05-25 | -2.7% | earnings | MarketBeat | Enliven Therapeutics (ELVN) Short Interest & Short Float | Updated Apr 2026 - MarketBeat |
| 2026-04-08 | +2.5% | M&A | Investing.com | H.C. Wainwright reiterates Enliven Therapeutics stock rating on Terns deal details - Investing.com |
| 2026-04-08 | +2.5% | M&A | Investing.com Australia | H.C. Wainwright reiterates Enliven Therapeutics stock rating on Terns deal details - Investing.com Australia |
| 2023-05-11 | -2.1% | earnings | Seeking Alpha | Enliven Therapeutics GAAP EPS of -$0.80 misses by $0.28 |
| 2025-03-13 | -2.0% | earnings | Seeking Alpha | Enliven Therapeutics GAAP EPS of -$0.46 |
| 2025-03-13 | -2.0% | news | PR Newswire | Enliven Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update - PR Newswire |
| 2026-01-14 | -2.0% | news | simplywall.st | Have Enliven Therapeutics Insiders Been Selling Stock? - simplywall.st |
| 2025-11-18 | +2.0% | news | Seeking Alpha | Enliven Therapeutics: Notable Early Signals, But Too Many Assumptions To Justify A Buy |
| 2025-11-18 | +2.0% | news | Seeking Alpha | Enliven Therapeutics: Notable Early Signals, But Too Many Assumptions To Justify A Buy - Seeking Alpha |
| 2026-03-03 | +1.8% | earnings | MT Newswires | Enliven Therapeutics Q4 Loss Widens |
| 2026-03-03 | +1.8% | news | PR Newswire | Enliven Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update |
| 2026-03-03 | +1.8% | earnings | Seeking Alpha | Enliven Therapeutics GAAP EPS of -$0.48 misses by $0.09 |
| 2026-03-03 | +1.8% | news | PR Newswire | Enliven Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update - PR Newswire |
| 2023-03-31 | -1.8% | earnings | MarketBeat | Enliven Therapeutics (ELVN) Insider Trading Activity 2026 - MarketBeat |
| 2026-03-30 | -1.6% | news | Simply Wall St. | Assessing Enliven Therapeutics (ELVN) Valuation After Strong Recent Share Price Momentum |
| 2024-01-31 | +1.4% | analyst | eToro | ELVN Stock Price | Analyst Target 51.67 & Consensus - eToro |
| 2026-04-17 | +1.4% | news | Insider Monkey | Enliven Therapeutics (ELVN) Up 194% This Year on Strong CML Market |
| 2026-04-17 | +1.4% | news | Yahoo Finance | Enliven Therapeutics (ELVN) Up 194% This Year on Strong CML Market - Yahoo Finance |
| 2025-01-07 | +1.3% | news | Seeking Alpha | Enliven Therapeutics: Still Too Early To Pay This Much |
| 2025-01-07 | +1.3% | news | Seeking Alpha | Enliven's Early Data Stands Out From Peers |
| 2024-05-15 | -1.3% | earnings | Seeking Alpha | Enliven Therapeutics GAAP EPS of -$0.54 beats by $0.02 |
| 2024-03-14 | -1.3% | earnings | Seeking Alpha | Enliven Therapeutics GAAP EPS of -$0.47 |
| 2024-04-18 | +1.0% | news | Seeking Alpha | Enliven Therapeutics files to sell 6.43M shares for holders |
| 2026-01-12 | -0.9% | news | Moomoo | Enliven Therapeutics(ELVN.US) Officer Sells US$3.48 Million in Common Stock - Moomoo |
| 2025-03-14 | +0.8% | news | Intellectia AI | ELVN Stock: Price, Forecast, Financials & AI Analysis - Intellectia AI |
| 2025-10-23 | -0.8% | news | Yahoo Finance | Assessing Enliven Therapeutics (ELVN) Valuation as Shares Show Signs of Short-Term Momentum - Yahoo Finance |
| 2025-06-16 | -0.6% | news | PR Newswire | Enliven Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares - PR Newswire |
| 2025-06-16 | -0.6% | news | Oncology Pipeline | EHA 2025 – ELVN-001 enlivens investors | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline |
| 2026-03-31 | -0.4% | news | Stock Titan | 25,000-share resale via Jefferies — Enliven Therapeutics (NASDAQ: ELVN) - Stock Titan |
| 2026-03-31 | -0.4% | legal | Stock Titan | [144] Enliven Therapeutics, Inc. SEC Filing - Stock Titan |
| 2026-03-31 | -0.4% | news | TipRanks | Why Enliven Therapeutics Stock Is Breaking Out Now - TipRanks |
| 2023-12-27 | +0.3% | analyst | TradingView | ELVN Forecast — Price Target — Prediction for 2027 - TradingView |
| 2026-04-03 | -0.2% | news | Cổng thông tin điện tử tỉnh Lào Cai | ELVN Stock Analysis: Enliven Therapeutics Rises 2.75 Pct to 38.83 in Biotech Rally - Cổng thông tin điện tử tỉnh Lào Cai |
| 2023-09-29 | -0.2% | news | Seeking Alpha | Enliven Therapeutics 10% owner disposes of ~$3M worth of shares |
| 2026-04-15 | +0.1% | news | Stock Titan | Enliven Therapeutics (NASDAQ: ELVN) asks shareholders to approve charter share increase - Stock Titan |